系统性硬化症患者疫苗接种建议的当前观点
Current Take on Systemic Sclerosis Patients' Vaccination Recommendations.
作者信息
Murdaca Giuseppe, Noberasco Giovanni, Olobardi Dario, Lunardi Claudio, Maule Matteo, Delfino Lorenzo, Triggiani Massimo, Cardamone Chiara, Benfaremo Devis, Moroncini Gianluca, Vacca Angelo, Susca Nicola, Gangemi Sebastiano, Quattrocchi Paola, Sticchi Laura, Icardi Giancarlo, Orsi Andrea
机构信息
Departments of Internal Medicine, University of Genova, 16132 Genova, Italy.
Department of Health Sciences, University of Genova, 16132 Genova, Italy.
出版信息
Vaccines (Basel). 2021 Dec 2;9(12):1426. doi: 10.3390/vaccines9121426.
Abstract
Systemic sclerosis (SSc) is a rare autoimmune inflammatory rheumatic disease. The prevalence of SSc ranges from 7 to 700 cases per million worldwide. Due to multiple organ involvement and constant inflammatory state, this group of patients presents an increased risk of infectious diseases. This paper aimed to gather the up-to-date evidence on vaccination strategies for patients with SSc and to be a useful tool for the prevention and management of infectious diseases. The authors conducted a scoping review in which each paragraph presents data on a specific vaccine's safety, immunogenicity, and efficacy. The work deals with the following topics: SARS-CoV-2, seasonal influenza, , HAV, HBV, HZV, , , HPV, and diphtheria-tetanus-pertussis.
摘要
系统性硬化症（SSc）是一种罕见的自身免疫性炎性风湿性疾病。全球范围内，SSc的患病率为每百万人7至700例。由于多器官受累以及持续的炎症状态，这类患者发生感染性疾病的风险增加。本文旨在收集关于SSc患者疫苗接种策略的最新证据，并成为预防和管理感染性疾病的有用工具。作者进行了一项范围综述，其中每一段都呈现了关于特定疫苗的安全性、免疫原性和有效性的数据。该研究涉及以下主题：严重急性呼吸综合征冠状病毒2（SARS-CoV-2）、季节性流感、甲型肝炎病毒（HAV）、乙型肝炎病毒（HBV）、带状疱疹病毒（HZV）、人乳头瘤病毒（HPV）以及白喉-破伤风-百日咳疫苗。
相似文献
1
Current Take on Systemic Sclerosis Patients' Vaccination Recommendations.系统性硬化症患者疫苗接种建议的当前观点
Vaccines (Basel). 2021 Dec 2;9(12):1426. doi: 10.3390/vaccines9121426.
2
Combined DTP-HBV-HIB vaccine versus separately administered DTP-HBV and HIB vaccines for primary prevention of diphtheria, tetanus, pertussis, hepatitis B and Haemophilus influenzae B (HIB).白喉、破伤风、百日咳、乙型肝炎和B型流感嗜血杆菌（HIB）联合疫苗与分别接种白喉、破伤风、百日咳、乙型肝炎疫苗和HIB疫苗用于白喉、破伤风、百日咳、乙型肝炎和B型流感嗜血杆菌（HIB）的一级预防。
Cochrane Database Syst Rev. 2009 Jul 8(3):CD005530. doi: 10.1002/14651858.CD005530.pub2.
3
Immunological persistence in 5 y olds previously vaccinated with hexavalent DTPa-HBV-IPV/Hib at 3, 5, and 11 months of age.5 岁时接种过 3、5、11 月龄六联苗（DTaP-HBV-IPV/Hib）的儿童的免疫持久性。
Hum Vaccin Immunother. 2014;10(10):2795-8. doi: 10.4161/21645515.2014.970494.
4
Integration of hexavalent diphtheria, tetanus, acellular pertussis, hepatitis B virus, inactivated poliomyelitis and Haemophilus influenzae type b conjugate vaccine within existing national recommendations following a birth dose of monovalent hepatitis B virus vaccine: results of a systematic review in the Asia Pacific region.在为新生儿接种单价乙型肝炎病毒疫苗后，根据现有国家建议，将六价白喉、破伤风、无细胞百日咳、乙型肝炎病毒、灭活脊髓灰质炎和流感嗜血杆菌 b 型结合疫苗进行整合：亚太地区系统评价的结果。
Expert Rev Vaccines. 2019 Sep;18(9):921-933. doi: 10.1080/14760584.2019.1646643. Epub 2019 Aug 1.
5
Safety profile of - 17 years of GSK's passive post-marketing surveillance.葛兰素史克17年被动上市后监测的安全性概况。
Expert Rev Vaccines. 2020 Aug;19(8):771-779. doi: 10.1080/14760584.2020.1800458. Epub 2020 Aug 10.
6
Immunogenicity and safety of an inactivated hepatitis A vaccine when coadministered with Diphtheria-tetanus-acellular pertussis and haemophilus influenzae type B vaccines in children 15 months of age.15 月龄儿童接种甲型肝炎灭活疫苗时同时接种白喉破伤风无细胞百日咳和乙型流感嗜血杆菌疫苗的免疫原性和安全性。
Pediatr Infect Dis J. 2011 Sep;30(9):e164-9. doi: 10.1097/INF.0b013e31821b8a7d.
7
Immunogenicity and safety of an inactivated hepatitis A vaccine administered concomitantly with diphtheria-tetanus-acellular pertussis and haemophilus influenzae type B vaccines to children less than 2 years of age.对2岁以下儿童同时接种甲型肝炎灭活疫苗与白喉-破伤风-无细胞百日咳疫苗和B型流感嗜血杆菌疫苗的免疫原性和安全性。
Pediatrics. 2006 Sep;118(3):e602-9. doi: 10.1542/peds.2005-2755.
8
Immunogenicity and Safety of Monovalent Acellular Pertussis Vaccine at Birth: A Randomized Clinical Trial.单剂无细胞百白破疫苗在出生时的免疫原性和安全性：一项随机临床试验。
JAMA Pediatr. 2018 Nov 1;172(11):1045-1052. doi: 10.1001/jamapediatrics.2018.2349.
9
Immunogenicity and safety of primary and booster vaccination with 2 investigational formulations of diphtheria, tetanus and Haemophilus influenzae type b antigens in a hexavalent DTPa-HBV-IPV/Hib combination vaccine in comparison with the licensed Infanrix hexa.与已获许可的六联疫苗（Infanrix hexa）相比，六价白喉-破伤风-无细胞百日咳-乙肝-脊髓灰质炎- b型流感嗜血杆菌联合疫苗（DTPa-HBV-IPV/Hib）中两种研究用白喉、破伤风和b型流感嗜血杆菌抗原制剂进行初次和加强免疫接种的免疫原性和安全性。
Hum Vaccin Immunother. 2017 Jul 3;13(7):1505-1515. doi: 10.1080/21645515.2017.1294294. Epub 2017 Mar 24.
10
Primary vaccination of infants against hepatitis B can be completed using a combined hexavalent diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliomyelitis-Haemophilus influenzae type B vaccine.婴儿的乙型肝炎基础疫苗接种可以使用一种联合的六价白喉-破伤风-无细胞百日咳-乙型肝炎-灭活脊髓灰质炎-乙型流感嗜血杆菌疫苗来完成。
Ann Acad Med Singap. 2007 Oct;36(10):801-6.
引用本文的文献
1
Hypogammaglobulinemia in patients affected by limited cutaneous systemic sclerosis: Case series and review of the literature.局限性皮肤型系统性硬化症患者的低丙种球蛋白血症：病例系列及文献综述
J Scleroderma Relat Disord. 2025 May 4:23971983251333851. doi: 10.1177/23971983251333851.
2
Challenges in Diagnosis of COVID-19 Pneumonia under Ocrelizumab and De-Risking Strategies in Multiple Sclerosis-The Elephant Is (Still) in the Room.奥瑞珠单抗治疗下COVID-19肺炎的诊断挑战及多发性硬化症的风险降低策略——大象仍在房间里。
Microorganisms. 2024 Sep 25;12(10):1941. doi: 10.3390/microorganisms12101941.
3
COVID-19 Vaccination Coverage and Associated Factors in Patients with Multiple Sclerosis.多发性硬化症患者的新冠病毒疫苗接种率及相关因素
Vaccines (Basel). 2024 Jan 26;12(2):126. doi: 10.3390/vaccines12020126.
4
Latent Class Analysis Identifies Distinct Phenotypes of Systemic Lupus Erythematosus Predictive of Flares after mRNA COVID-19 Vaccination: Results from the Coronavirus National Vaccine Registry for ImmuNe Diseases SINGapore (CONVIN-SING).潜在类别分析确定系统性红斑狼疮的不同表型，这些表型可预测mRNA新冠疫苗接种后的病情发作：来自新加坡免疫疾病冠状病毒国家疫苗登记处（CONVIN-SING）的结果。
Vaccines (Basel). 2023 Dec 27;12(1):29. doi: 10.3390/vaccines12010029.
5
Impact of an Intervention to Promote the Vaccination of Patients with Inflammatory Bowel Disease.一项促进炎症性肠病患者接种疫苗干预措施的影响
Vaccines (Basel). 2023 Oct 27;11(11):1649. doi: 10.3390/vaccines11111649.
6
SARS-CoV-2 infection risk is higher in vaccinated patients with inflammatory autoimmune diseases or liver transplantation treated with mycophenolate due to an impaired antiviral immune response: results of the extended follow up of the RIVALSA prospective cohort.由于抗病毒免疫反应受损，接受霉酚酸酯治疗的炎症性自身免疫性疾病或肝移植的疫苗接种患者 SARS-CoV-2 感染风险更高：前瞻性 RIVALSA 队列扩展随访的结果。
Front Immunol. 2023 Jul 20;14:1185278. doi: 10.3389/fimmu.2023.1185278. eCollection 2023.
7
The Trajectory of Brazilian Immunization Program between 1980 and 2018: From the Virtuous Cycle to the Vaccine Coverage Decline.1980年至2018年巴西免疫规划的轨迹：从良性循环到疫苗接种覆盖率下降。
Vaccines (Basel). 2023 Jul 1;11(7):1189. doi: 10.3390/vaccines11071189.
8
Impact of SARS-CoV2 infection on anti-apolipoprotein A-1 IgG response in inflammatory rheumatic diseases.SARS-CoV-2 感染对炎症性风湿病患者抗载脂蛋白 A-1 IgG 应答的影响。
Front Immunol. 2023 May 10;14:1154058. doi: 10.3389/fimmu.2023.1154058. eCollection 2023.
9
Potent NTD-Targeting Neutralizing Antibodies against SARS-CoV-2 Selected from a Synthetic Immune System.从合成免疫系统中筛选出的针对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的强效靶向N端结构域（NTD）中和抗体。
Vaccines (Basel). 2023 Mar 31;11(4):771. doi: 10.3390/vaccines11040771.
10
Myocardial infarction or myocarditis? A case report and review of a myocardial adverse event associated with mRNA vaccine.心肌梗死还是心肌炎？一例与mRNA疫苗相关的心肌不良事件的病例报告及文献综述。
Front Med (Lausanne). 2023 Feb 2;10:1071239. doi: 10.3389/fmed.2023.1071239. eCollection 2023.
本文引用的文献
1
Surveillance for Adverse Events After COVID-19 mRNA Vaccination.COVID-19 mRNA 疫苗接种后不良事件的监测。
JAMA. 2021 Oct 12;326(14):1390-1399. doi: 10.1001/jama.2021.15072.
2
Use of mRNA COVID-19 Vaccine After Reports of Myocarditis Among Vaccine Recipients: Update from the Advisory Committee on Immunization Practices - United States, June 2021.mRNA COVID-19 疫苗接种后出现心肌炎报告：免疫实践咨询委员会更新-美国，2021 年 6 月。
MMWR Morb Mortal Wkly Rep. 2021 Jul 9;70(27):977-982. doi: 10.15585/mmwr.mm7027e2.
3
Incidence of Multisystem Inflammatory Syndrome in Children Among US Persons Infected With SARS-CoV-2.美国 SARS-CoV-2 感染人群中儿童多系统炎症综合征的发病率。
JAMA Netw Open. 2021 Jun 1;4(6):e2116420. doi: 10.1001/jamanetworkopen.2021.16420.
4
Canadian Rheumatology Association Recommendation for the Use of COVID-19 Vaccination for Patients With Autoimmune Rheumatic Diseases.加拿大风湿病学会关于自身免疫性风湿病患者使用 COVID-19 疫苗的建议。
J Rheumatol. 2021 Aug;48(8):1330-1339. doi: 10.3899/jrheum.210288. Epub 2021 May 15.
5
Reactogenicity Following Receipt of mRNA-Based COVID-19 Vaccines.接种基于mRNA的COVID-19疫苗后的反应原性。
JAMA. 2021 Jun 1;325(21):2201-2202. doi: 10.1001/jama.2021.5374.
6
COVID-19 vaccination and antirheumatic therapy.COVID-19 疫苗接种和抗风湿治疗。
Rheumatology (Oxford). 2021 Aug 2;60(8):3496-3502. doi: 10.1093/rheumatology/keab223.
7
Recommendations for the use of COVID-19 vaccines in patients with immune-mediated kidney diseases.免疫介导性肾脏病患者使用新型冠状病毒肺炎疫苗的建议。
Nephrol Dial Transplant. 2021 Mar 9. doi: 10.1093/ndt/gfab064.
8
SARS-CoV-2 Vaccines.严重急性呼吸综合征冠状病毒2型疫苗
JAMA. 2021 Apr 6;325(13):1318-1320. doi: 10.1001/jama.2021.3199.
9
EULAR December 2020 viewpoints on SARS-CoV-2 vaccination in patients with RMDs.欧洲抗风湿病联盟2020年12月关于风湿病患者接种新型冠状病毒疫苗的观点
Ann Rheum Dis. 2021 Apr;80(4):411-412. doi: 10.1136/annrheumdis-2020-219773. Epub 2021 Feb 9.
10
Pneumococcal Pneumonia and Invasive Pneumococcal Disease in Those 65 and Older: Rates of Detection, Risk Factors, Vaccine Effectiveness, Hospitalisation and Mortality.65岁及以上人群的肺炎球菌肺炎和侵袭性肺炎球菌病：检出率、危险因素、疫苗效力、住院率和死亡率
Geriatrics (Basel). 2021 Feb 4;6(1):13. doi: 10.3390/geriatrics6010013.
Zotero 插件